The global mycoplasma testing market offers a wide range of products that play a vital role in pharmaceutical, biotechnology and research industries by detecting and eliminating mycoplasma contamination in cell culture. Cell-based assays are commonly used in the development and manufacturing of biotherapeutic products and detecting mycoplasma is crucial to ensure product quality and safety. The market provides kits and reagents for polymerase chain reaction (PCR)-based, microbiological and non-microbiological techniques for mycoplasma detection procedures. Advancements in PCR-based detection methods have significantly improved sensitivity and reduced the time required for testing.

The Global Mycoplasma Testing Market Sizeis estimated to be valued at US$ 997.8 MN in 2024 and is expected to exhibit a CAGR of 9.7% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Global Mycoplasma Testing Market Size are Charles River Laboratories International, Merck KGaA, Lonza Group Ltd, Roche Diagnostics, Thermo Fisher Scientific, Merck, InvivoGen, Creative Bioarray.

The market offers opportunities for growth driven by rising R&D investments in cell-based research and biologics manufacturing. Additionally, stringent regulations requiring mycoplasma testing at different stages of product development and manufacturing further support market expansion.

Technological advancements in PCR and other detection techniques have made mycoplasma testing more sensitive and high-throughput. Introduction of microfluidics-based PCR systems and automated detection platforms are expected to boost adoption rates.

Get more insights on This Topic- Global Mycoplasma Testing Market